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Abstract
Background: Exercise-based therapy is known to enhance motor recovery after stroke but the most appropriate
amount, i.e. the dose, of therapy is unknown. To determine the strength of current evidence for provision of a
higher dose of the same types of exercise-based therapy to enhance motor recovery after stroke.
Methods: An electronic search of: MEDLINE, EMBASE, CINHAL, AMED, and CENTRAL was undertaken. Two
independent reviewers selected studies using predetermined inclusion criteria: randomised or quasi randomised
controlled trials with or without blinding of assessors; adults, 18+ years, with a clinical diagnosis of stroke;
experimental and control group interventions identical except for dose; exercise-based interventions investigated;
and outcome measures of motor impairment, movement control or functional activity. Two reviewers
independently extracted outcome and follow-up data. Effect sizes and 95% confidence intervals were interpreted
with reference to risk of bias in included studies.
Results: 9 papers reporting 7 studies were included. Only 3 of the 7 included studies had all design elements
assessed as low risk of bias. Intensity of the control intervention ranged from a mean of 9 to 28 hours over a
maximum of 20 weeks. Experimental groups received between 14 and 92 hours of therapy over a maximum of 20
weeks. The included studies were heterogeneous with respect to types of therapy, outcome measures and time-
points for outcome and follow-up. Consequently, most effect sizes relate to one study only. Single study effect
sizes suggest a trend for better recovery with increased dose at the end of therapy but this trend was less evident
at follow-up Meta-analysis was possible at outcome for: hand-grip strength, -10.1 [-19.1,-1.2] (2 studies, 97
participants); Action Research Arm Test (ARAT), 0.1 [-5.7,6.0] (3 studies, 126 participants); and comfortable walking
speed, 0.3 [0.1,0.5] (2 studies, 58 participants). At follow-up, between 12 and 26 weeks after start of therapy, meta-
analysis findings were: Motricity Arm, 10.7 [1.7,19.8] (2 studies, 83 participants); ARAT, 2.2 [-6.0,10.4] (2 studies, 83
participants); Rivermead Mobility, 1.0 [-0.6, 2.5] (2 studies, 83 participants); and comfortable walking speed, 0.2
[0.0,0.4] (2 studies, 60 participants).
Conclusions: Current evidence provides some, but limited, support for the hypothesis that a higher dose of the same
type of exercised-based therapy enhances motor recovery after stroke. Prospective dose-finding studies are required.
Background
Exercise-based therapy is known to enhance motor
recovery after stroke but the most appropriate amount,
i.e. the dose, of therapy is unknown. There is strong
clinical opinion that if higher doses of exercise-based
therapy could be provided then motor outcome would
be improved.
The possibility of a dose-response relationship
between exercise-based therapy and motor recovery is
supported by the findings of several systematic reviews
[1-5]. However, some of the included trials in all of the
published systematic reviews were not designed pri-
marily to evaluate different doses of the same therapy.
R a t h e r ,t h e yw e r ed e s i g n e dt oe v a l u a t ee i t h e rd i f f e r e n t
types of therapy, augmentation of one therapy with
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no treatment. Consequently, the results of these sys-
tematic reviews are confounded by examination of dif-
f e r e n tt y p e sa sw e l la sd i f f e r e nt intensities of therapies.
Differentiation of the effects of different types and dif-
ferent intensities of exercise-based therapies is
required.
In contrast to widely-held clinical opinion and conclu-
sions of systematic reviews an increased dose of con-
straint-induced movement therapy (CIMT) given early
after stroke resulted in a worse outcome than either a
smaller dose of CMIT or a smaller dose of conventional
therapy [6]. This unexpected finding echoes those from
animal model studies which indicate that a high usage
of a paretic forelimb early after experimental stroke is
associated with a poorer motor outcome and an increase
in size of the brain lesion [7-9] if it is provided early
after stroke [10]. It is possible, therefore, that high doses
of exercise-based therapy could be detrimental for
motor recovery after stroke. This is not the only possibi-
lity, however, as experimental animal model studies
indicate that more activity, provided in enriched envir-
onments, enhances motor recovery more than a stan-
dard housing environment [11]. In addition, preliminary
investigation suggests the existence of a moderate rela-
tionship (r = 0.45, p < 0.01) between the number of
repetitions of an exercise and improvement in motor
function [12], post-hoc analysis of three separate
research studies of the same therapy suggests greater
benefit for a higher dose [13] and an exploratory study
suggests benefit from higher dose of CIMT for people
who were later after stroke [14] than were participants
in the recent trial [6].
Whether an increased dose of exercise-based therapy
is beneficial, detrimental or makes no difference to
motor recovery after stroke needs to be elucidated. Well
designed studies of different doses of the same therapy
at different times after stroke in well characterised
groups of stroke survivors are required. Before under-
taking such studies a systematic review specifically
investigating the effect of increased dose of exercise
therapy is required to establish the current evidence-
base. This paper reports a systematic review and meta-
analysis designed to determine the strength of current
evidence for providing a higher intensity of the same
types of exercise-based therapy to enhance motor recov-
ery after stroke.
Methods
Design
The design of this systematic review followed recom-
mendations of the Cochane Collaboration. The review
protocol was not published prior to this report other
than as part of a PhD thesis [15].
Search strategy
The following databases were searched electronically; US
National Library of Medicine Database (MEDLINE);
European Medical Database (EMBASE); Cumulative
Index to Nursing and Allied Health Literature (CIN-
HAL); Allied and Complementary Medicine Database
(AMED); and Cochrane Central Register of Controlled
Trials (CENTRAL). An example of the search strategy
used is given in Table 1. The initial search was con-
ducted to cover the time period from induction of the
databases to November 2008 and this was updated in a
subsequent search to include the period up to October
2009. The updated search (December 2008 to October
2009) did not include CINHAL because the host had
c h a n g e df r o mO V I D .Ad e c i s i o nw a sm a d en o tt o
update the CINHAL search because records identified
through it in the initial search were also found in other
databases.
Table 1 Search strategy for electronic databases
1. exp Stroke/
2. stroke.mp.
3. cerebrovascular diseas$.mp.
4. cerebral vascular diseas$.mp.
5. cerebral vascular accident$.mp.
6. cerebrovascular accident$.mp.
7. (hemipleg$ or hemipar$).mp.
8. 6 or 4 or 1 or 3 or 7 or 2 or 5
9. exp Physical Therapy
Modalities/
10 physiotherapy.mp.
11. physical therapy.mp.
12. 11 or 10 or 9
13. randomized controlled trial.pt.
14. controlled clinical trial.pt.
15. randomised controlled trials.sh.
16. random allocation.sh.
17. double-blind method.sh.
18. single-blind method.sh.
19. 18 or 16 or 13 or 17 or 12 or
15 or 14
20. clinical trial.pt.
21. exp Clinical Trial/
22. ((singl$ or doubl$ or treb$ or
trip$) adj25 (blind$ or mask$)).ti,
ab.
23. (clin$ adj25 trial$).ti, ab.
24. placebo$.ti, ab.
25. placebo.sh.
26. random$.ti, ab.
27. research design.sh.
28. 27 or 25 or 21 or 26 or 20 or
22 or 24 or 23
29. comparative study.sh.
30. exp Evaluation Studies/
31. follow up studies.sh.
32. (contro$ or prospectiv$ or
volunteer$).ti, ab.
33. 32 or 30 or 31 or 29
34. 33 or 28 or 19
35. exercis$.mp.
36. exercis$.sh.
37. exp Exercise/
38. functional strength train$.mp.
39. activities of daily living.mp.
40. neuro facilitation.mp.
41. bobath therap$.mp.
42. motor relearn$.mp.
43. rehabilitation.mp.
44. rehabilitation.sh.
45. exp Rehabilitation/
46. restoration of function$.mp.
47. 35 or 39 or 40 or 36 or 41 or 38
or 42 or 46 or 45 or 37 or 43 or 44
48. intensit$.mp.
49. intensit$.sh.
50. frequenc$.sh.
51. frequenc$.mp.
52. duration.mp.
53. duration.sh.
54. dose.mp.
55. dosage.mp.
56. amount.mp.
57. quantit$.mp.
58. how much.mp.
59. dos$.mp.
60. dosing.mp.
61. doses.mp.
62. amounts.mp.
63. 63. 50 or 53 or 57 or 61 or 51
or 58 or 48 or 59 or 52 or 60 or
56 or 49 or 62 or 54 or 55
64. 64. 8 and 63 and 34 and 12 and
47
Abbreviations
mp = title, original title, abstract, name of substance word, subject heading
word.
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Page 2 of 13Reference lists of all articles reporting included trials
were searched for any extra possibly relevant records. If
any records were identified from the hand searching of
reference lists and they came from journals not included
on the CENTRAL data base, the contents pages of those
journals were hand searched. A hand search of our own
private databases of references was also undertaken. In
addition authors of included articles were contacted for
any unpublished data.
Criteria for inclusion of trials
Types of trial
Randomised or quasi randomised controlled trials with
or without blinding of assessors;
Types of participants
Adults, aged over 18 years, with a clinical diagnosis of
stroke
Types of interventions
￿ Experimental and control group interventions identical
except for dose. Therapy dose can be described in terms
of time spent in therapy and/or of effort expended [16].
Description of time includes: minutes per session; ses-
sions per day/week; and number of days/weeks [16].
Description of effort can be made in terms of the work
or power required to perform an exercise for example,
resistance training and the amount of weight used [16].
For this systematic review dose refers to the total time
spent in exercise-based therapy.
￿ Interventions investigated were exercise-based (no
electrostimulation, splinting or orthotics) to facilitate
muscle activity or functional ability;
Types of outcome measures
￿ Measure of motor impairment - muscle function. For
example. Motricity Index, muscle tone, joint range of
motion;
￿ Measures of motor impairment - movement control.
For example. co-ordination, reaction time;
￿ Measure of motor activity. For example. Modified
Rivermead Mobility Index, Action Research Arm Test,
Functional Ambulation Categories, 9 Hole Peg Test.
Trial selection
The identification of relevant trials was undertaken by
two reviewers independently using the pre-set inclusion
criteria set out on a predesigned form. Reviewers
assessed the record titles and categorised each as ‘defi-
nitely relevant’, ‘possibly relevant’ or ‘definitely irrele-
vant’. Any title that both reviewers ranked ‘definitely
irrelevant’ was excluded. The reviewers repeated the
categorisation process for abstracts and full papers in
turn. They did not use the category possibly relevant for
the full papers. Any disagreements between the
reviewers were resolved through referral to full papers
and discussion. Trials reported in full papers which
were categorised as ‘definitely irrelevant’ by both
reviewers were excluded and reasons documented. Trials
which both reviewers categorised as ‘definitely relevant’
were classified as included trials for evaluation in this
systematic review.
Assessment of risk of bias
Assessment of the risk of bias in included trials was
undertaken by two reviewers independently for design
features using the tool developed by the Cochrane Col-
laboration [17]. Any disagreements between reviewers
were resolved by discussion, referral to full papers and
contact with authors for clarification where necessary.
A risk of bias plot was produced for the review using
categories of low, unclear or high risk.
Data Extraction
Data extraction was undertaken by two reviewers inde-
pendently using a predesigned form. Any disagreements
were resolved by discussion and referral to the original
full papers. Trial authors were contacted to clarify
results when this was necessary and possible. Data was
extracted on:
￿ Trial design, sample size and attrition;
￿ Participant characteristics’ e.g. age, gender, site of
lesion, stroke classification;
￿ Type of interventions;
￿ Dose of interventions (sum of treatment hours);
￿ Measures made at outcome (end of intervention per-
iod) and follow-up time-points in terms of average
scores for trial groups.
Statistical analysis of outcome and follow-up data
Analysis was undertaken, where possible, on an inten-
tion- to-treat basis. Trials were not excluded if data was
unavailable for subjects who did not complete all the
outcome measures. Data analysis was undertaken using
the Cochrane statistical package RevMan 4.2.
Effect sizes were calculated as odds ratios (OR) and
95% confidence interval (CI) for dichotomous outcomes
and as weighted mean differences (WMD and 95% CI)
for continuous outcomes. WMDs were determined initi-
ally using a Fixed Effect Model. Where two or more
trials had used the same outcome measure, however,
and if there was evidence of heterogeneity, the WMDs
were estimated from a Random Effects Model. Where it
was not possible to combine and compare the outcome
measures reported in different trials, then statistical
results were described and tabulated individually. Sub-
groups were formed by each follow-up time point. No
overall analysis was done since this would involve com-
bining subgroups based on the same individuals and
could bias the results.
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The results of the statistical analysis were interpreted
with reference to the risk of bias in trials, and compar-
ability of participants, types of interventions and dose of
interventions.
Results
Full details of the number of records screened and stu-
dies included in this review are given in Figure 1. In
summary, 940 potentially relevant records were screened
and 31 potentially relevant records were identified.
Twenty-two records did not meet the inclusion criteria
and are listed in Table 2 alongside the reasons for their
omission from this review. The remaining nine records
were articles reporting seven studies (three articles
reported different aspects of the same study [17-19].
Therefore nine articles reporting seven studies have
been included in this review [18-26] (Fig 1).
Study designs
Of the 7 included studies three used a multi-centre,
observer-blind randomised controlled design. The
remaining four studies used a single-centre, observer-
blind randomised controlled design (Table 3)
Participants
The seven studies included 680 participants (range 20-
189) who completed baseline measurements (Table 3).
One trial provided additional therapy from a qualified
therapist and an assistant, but only the subjects treated
by the qualified therapist are included in this review to
ensure comparability with the other studies [22]. The
mean age of participants in the seven studies ranged
from 65.9 years [18-20] to 76.5 years [22] and time
since stroke on admission to studies ranged from a
median of 5 days [24] to a mean of 35 days [26]
(Table 3). Full details of participant characteristics are
provided in Table 3.
Interventions
Four of the studies described the intervention as a
‘normal movement’ (Bobath) approach [21-24], two
studies investigated conventional physical therapy as
used in the UK [25,26] and one study based the inter-
vention on an eclectic approach involving task specific
training regime following stroke [18-20] (Table 4). The
dose of the exercise-based intervention was described
in terms of intensity (minutes per day), frequency
(times per week), duration (number of weeks). From
this the total dose was calculated. The dose of the con-
trol intervention was not provided in two studies
[22,23]. The dose of the control intervention in the
remaining five studies ranged from a mean of 9.2
hours [26] to 27.5 hours [18-20]. The mean dose
received by the experimental groups (control plus
extra) ranged from 13.8 hours [25]
D to 91.8 hours
[18-20]. Details are provided in Table 4.
Assessment of potential bias
The results of the assessment of potential bias are pre-
sented in Table 5. In summary, only 3 of the 7 included
studies had all design elements assessed as low risk of
bias. Of note are:
1. The blinding procedure used in one study [24] was
assessed as presenting a potential high risk of bias
because in the discussion section of the paper it is stated
that clinical therapists were not blind to treatment allo-
cation and therefore gave more uni-disciplinary treat-
ment to those participants who were receiving less
therapy in the trial.
2. Allocation concealment procedures used in two stu-
dies [18-20,22] were unclear as there were no specific
statements about this aspect of randomisation procedure
e.g. use of sealed opaque envelopes
3. Incomplete outcome data is possibly present in two
studies [22,23] but this is unclear from information pre-
sented in the papers. In one trial [22] it was reported
that a number of participants died yet there was no
reference to the process used for analysis for drop outs.
Indeed the results tables suggest that all participants
were included in the outcome analysis. One trial [23]
provided no reasons for withdrawals and no methods
Figure 1 Flow Diagram for this systematic review (note: 3 full-
text articles reported the same study).
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surement time-points.
4. One trial appeared to report outcomes selectively
[23]. Specifically step-time ratio was included in list of
outcomes to be measured yet was not reported in the
results section. Also sit-to-stand time, timed walk and
functional reach were not measured at baseline yet there
was no explanation as to why these were omitted.
Outcomes
Extraction of data for one study [18-20] was undertaken
considering its 3-group design of placebo, extra arm
therapy and extra leg therapy and that all participants
undertook all measures. In this present review we con-
sidered that the placebo group would act as a control
for both experimental groups but that data extracted for
the arm group would be that specific to the upper limb
and data extracted for the leg group would be that spe-
cific to the lower limb. Consequently data analysed in
this present review does not include upper limb mea-
sures reported for the leg group and vice versa. Two
other studies also used a 3-group design [25,26] to
compare different types and different doses of physical
therapy. The data extracted from these for this review
consists of that for the groups receiving the routine
amount and extra amount of conventional physical
therapy.
The time-points for outcome measures were mostly
comparable as they were made between 4 and 6 weeks
after the start of therapy except for one study where
treatment was provided for 20 weeks [18-20] (Table 4)
At follow-up 1 there was more variety between studies
with time-points ranging from 12 to 26 weeks after the
start of treatment and also 3 months after stroke (Table
4). Follow-up 2 time-points were either 6 months after
start of treatment, 52 weeks after start of treatment or 6
months after stroke (Table 4).
1. Motor impairment - muscle function (Table 6)
Heterogeneity between studies in use of specific
measures limited meta-analysis. At outcome there
was a trend towards benefit for a higher dose of
therapy but effect sizes for 5 of the 10 comparisons
were not statistically significant. Significant effect
Table 2 Excluded Studies
Study Reason for Exclusion
Ada 2006 Not a randomised controlled trial.
Barreca 2004 Treatment interventions between control and experimental group differed in content.
Dromerick 2009 Interventions included different time periods for wearing of mitt (not an exercise based intervention) and different doses of
shaping, therefore, unable to determine which aspect of this intervention would contribute to functional outcomes.
Duncan 2003 Treatment interventions between control and experimental group differed in content.
Fang 2003 Control group received no intervention, therefore study investigated effects of physiotherapy rather than an increased intensity
of physiotherapy.
Feys 1998 Investigated the effects of an intervention not intensity.
Fisher 2001 Not a randomised controlled trial.
Green 2002 Investigated the effect of an intervention in a specific setting not intensity.
Kuys 2008 Not a randomised controlled trial.
Kwakkel 2002 Examination of a subgroup of the original trial (Kwakkel 1999).
Moreland 2003 Progressive resisted exercise - not the definition of intensity used in this review.
Nugent 1994 Not a controlled or randomised controlled trial.
Page 2004 Investigated the effect of an intervention not intensity.
Richards1993 Treatment interventions between control and experimental group differed in content.
Richards 2008 Not a randomised controlled trial.
Sivenius 1985 Extra therapy incorporated components of physical, occupational and speech therapy. It was not possible to isolate the effects
of exercise-based therapy.
Slade 2002 Therapy analysed included physical, perceptual and cognitive, washing and dressing, daily living activities, group treatment, joint
treatment and splinting and this was analysed as ‘a package’. It was not possible to isolate the effects of exercise-based therapy.
Smith 1981 No specific treatment techniques described. Intensive therapy involved multi disciplinary treatment and therefore difficult to
isolate the effects of exercise-based therapy. Control group also given extra treatment if deemed necessary.
Sunderland 1992 Treatment interventions between control and experimental group differed in content. The experimental group also included
EMG biofeedback.
Wade 1992 Subjects received physiotherapy immediately or after three months delay, therefore effectively the first half of a crossover study
- physiotherapy versus no treatment. Therefore not different intensities of the same physiotherapy treatment.
Werner 2002 Treatment interventions between control and experimental group differed in content.
Wolf 2007 Not a randomised controlled trial.
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Study Design Participants Attrition
(cumulative)
Number & gender Mean (SD)
age (years)
Stroke lesioned
hemisphere
Stroke classification Mean (SD) time
after stroke
(days)
Control Extra Control Extra Control Extra Control Extra Control Extra Control Extra
Cooke 2009 Multi-centre
Observer- blind
RCT
38 (21 M) 35 (22 M) 66.4 (13.7) 67.5 (11.3) 17 right 13 right All anterior circulation
stroke
36.8
(22.5)
32.4
(21.3)
7 by 6 weeks
21 by 6
weeks
3 by 6 weeks
10 by 12
weeks
Donaldson 2009 Single centre
Observer- blind
RCT
10 (5 M) 10 (5 M) 72.7 (14.5) 73.0 (8.6) 5 right 4 right All anterior circulation
stroke
13.4
(4.4)
25.6
(15.5)
2 by 6 weeks
7b y1 2
weeks
0 by 6 weeks
4b y1 2
weeks
GAPS 2004 Multi-centre
Observer- blind
RCT
35 (17 M) 35 (24 M) 67 (10) 68 (11) 15 right 15 right TACI = 7
PACI = 18
LACI = 8
POCI = 1
unsure =
1
TACI = 6
PACI = 15
LACI = 10
POCI = 2
unsure =
2
25 days
(range 6-71)
0 by 4 weeks
1b y3
months
1b y6
months
1 by 4 weeks
3b y3
months
4b y6
months
Lincoln 1999 Single centre
Observer- blind
RCT
95 (45 M) 94 (51 M) Median 73
(IQR 64-80)
Median 73
(IQR 65-81)
38 right 47 right TACI = 7
PACI = 29
LACI = 13
POCI = 0
unsure =
46
TACI = 9
PACI = 31
LACI = 11
POCI = 0
unsure =
43
1-5 weeks after
stroke
5 by 5 weeks
11 by 3
months
14 by 6
months
7 by 5 weeks
10 by 3
months
13 by 6
months
Kwakkel 1999 &
2002
Multi-centre
Observer- blind
RCT
37 (14 M) Arm group
33 (16 M)
64.1 (15) Arm group
69 (9.8)
24 right Arm
group
19 right
TACI = 25
PACI = 9
LACI = 3
POCI = 0
unsure =
0
Arm
group
TACI = 19
PACI = 11
LACI = 3
POCI = 0
unsure =
0
7.5 (2.9) Arm
group
7.2 (2.8)
3b y2 0
weeks
3b y2 6
weeks
4b y5 2
weeks
Arm group
4b y2 0
weeks
4b y2 6
weeks
5b y5 2
weeks
Leg group
21 (13 M)
Leg group
64.5 (9.7)
Leg
group
18 right
Leg group
TACI = 17
PACI = 13
LACI = 1
POCI = 0
unsure =
0
Leg
group
7.0 (2.5)
Leg group
5b y2 0
weeks
5b y2 6
weeks
6b y5 2
weeks
Partridge 2000 Single centre
Observer- blind
RCT
60 54 76.5 (range 60 - 90) 53 right No data provided in
paper
No data provided
in paper
4 by 6 weeks
11 by 6
months
2 by 6 weeks
10 by 6
months
(52 M)
Rodgers 2003 Single centre
Observer- blind
RCT
61 (30 M) 62 (28 M) Median 75
(no range
provided)
Median 74 (no range
provided)
35 right 34 right TACI = 13
PACI = 17
LACI = 29
POCI = 2
unsure =
0
TACI = 8
PACI = 17
LACI = 34
POCI = 3
unsure =
0
Median of 5 days
after stroke
10 by 3
months
13 by 6
months
8b y3
months
14 by 6
months
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3Table 4 Included studies interventions, intensity and outcome measures
Study Intervention Intensity - mean hours
delivered (SD)
Measurement time points Outcome measures
Control Extra Control Extra Baseline Outcome Follow-up 1 Follow-up 2
Cooke 2009 Conventional physical therapy -
lower limb from usual staff
9.2
(6.9)
23.0 (10.4) Pre-
intervention
After 6 weeks of
intervention
12 weeks after end
treatment
NA ▪ Walking speed
▪ Ability to walk at 0.8 m/s
or more
▪ Modified Rivermead
Mobility Index
▪ Knee flexion peak torque
▪ Knee extension peak
torque
Extra from research staff
Donaldson
2009
Conventional physical therapy -
upper limb from usual staff
2.81
(3.7)
13.8
(27.1)
Pre-
intervention
After 6 weeks of
intervention
12 weeks after end
treatment
▪ Action Research Arm Test
▪ 9 hole peg test
▪ Hand grip force
▪ Pinch grip force
▪ Elbow flexion force -
isometric
▪ Elbow extension force -
isometric
Extra from research staff
GAPS 2004 Treatment broadly based on
‘normal movement’ (Bobath
approach) from usual staff.
Average
21
(no
data)
Average 34
(no data)
Pre-
intervention
After 4 weeks of
intervention
3 months after start
treatment
6 months after start
treatment
▪ Rivermead Mobility Index
▪ Motricty Index
Lincoln 1999 Treatment based on the Bobath
approach from usual staff
No data Median 9.58 extra
to control
(IQR 4.7-10)
Pre-
intervention
After 5 weeks of
intervention
3 months after start
treatment
6 months after start
treatment
▪ Rivermead Arm
Assessment
▪ Action Research Arm Test
▪ Rivermead Motor Assess -
gross function
▪ 10-hole Peg Teat
▪ Maximum grip strength
Extra from research staff
Kwakkel 1999
& 2002
Routine arm & leg training using
evidenced-based guidelines from
usual staff
27.5 arm
&
23.2 leg*
Arm group
91.8*
Pre-
intervention
After 20 weeks
treatment
26 weeks after start
treatment
52 weeks after start
treatment
Arm group
▪ Action Research Arm Test
▪ Frenchay Activities Index
Arm group
Arm training from usual
staffLeg group
Leg training from usual
staff
leg*
Leg group
84.2*
Leg group
▪ Comfortable walking speed
▪ Maximum walking speed
▪ Functional Ambulation
Categories
Partridge 2000 Bobath method of treatment from
usual staff
No data No data Pre-
intervention
After 6 weeks of
intervention
6 months after start
treatment
NA ▪ Functional reach
▪ 5-metre timed walk
▪ Timed sit-to-stand
Rodgers 2003 Normal movement approach
(Bobath) within meaningful activity
and task analysis from usual staff
17.4 24.9 Pre-
intervention
None 3 months after
stroke
6 months after
stroke
▪ Action Research Arm Test
▪ Upper Limb Motricity Index
▪ Frenchay Arm Test
* calculated using minutes/day data 20 weeks each with 5 treatment days.
$ calculated using median 30 days with 0.58 hours a day for control and 0.83 hours a day for extra.
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city Index Leg score, 23.0 [10.0,35.9]; Motricity
Index Arm score, 24.1 [9.2,33.1]; knee extension tor-
que, 17.5 [1.1,33.9], knee flexion torque, 15.0
[3.7,26.3]; and hand grip strength, -11.0 [-20.2,-1.8].
Meta-analysis was only possible for hand grip force/
strength (2 studies) and this found a benefit for the
standard dose of therapy, -10.1 [-19.1,1.2].
At follow-up 1 the trend toward benefit for a higher
dose of therapy remained but only two of the seven
individual effects sizes were significant. These were
both from the same study [18-20] Motricity Index
Leg score, 41.0 [27.7,54.3]; and Motricity Index Arm
score, 17.5 [2.3,32.7]. Meta-analysis was only possible
for Motricity Index Arm score (two studies) and the
effect size was 10.7 [1.7,19.8].,
Table 5 Risk of bias for included studies
Cooke
2009
Donaldson
2009
GAPS
2004
Lincoln
1999
Kwakkel 1999 &
2002
Partridge
2000
Rodgers
2000
Sequence generation low low low low low low low
Allocation concealment low low low unclear unclear low low
Blinding (participants, personnel and
assessors)
low low low low low low high
Incomplete outcome data low low low unclear low unclear low
Selective outcome reporting low low low low low high low
Other sources of bias low low low low low low low
Table 6 Motor impairment - muscle function
Time-point Study Measure used Augmented therapy Standard therapy Mean difference
Number
subjects
Mean (SD) Number
subjects
Mean (SD) Effect
size
[95% CI]
Outcome
4 weeks after start therapy GAPS Motricity arm + leg 33 119.0 (46.0) 34 111.0 (45.0) 8.0 [-13.8,29.8]
20 weeks after start therapy Kwakkel Motricity leg 26 68.2 (25.8) 34 45.2 (24.8) 23.0 [10.0,35.9]
20 weeks after start therapy Kwakkel Motricity arm 29 53.1 (32.0) 34 28.9 (28.5) 24.2 [9.2,33.1]
6 weeks after start therapy Donaldson Hand grip force 10 71.9 (49.5) 8 64.8 (39.3) 7.1 [-34.0,48.1]
5 weeks after start therapy Lincoln Hand grip strength 87 0 (25.19) 90 11.0 (36.3) -11.0 [-20.2,-1.8]
Subtotal - hand grip force/
strength
97 98 -10.1 [-19.1,-1.2]
6 weeks after start therapy Donaldson Pinch grip force 10 31.5 (23.1) 8 24.5 (19.7) 7.0 [-12.8,26.8]
6 weeks after start therapy Donaldson Elbow extend force 10 64.5 (44.6) 8 68.6 (39.6) -4.1 [-43.1,34.8]
6 weeks after start therapy Donaldson Elbow flexion force 10 76.1 (58.7) 8 75.0 (38.7) 1.1 [-44.1,46.3]
6 weeks after start therapy Cooke Knee extend
torque
26 45.3 (33.2) 25 27.8 (26.3) 17.5
a [1.1, 33.9]
6 weeks after start therapy Cooke Knee flexion torque 26 34.0 (23.1) 25 19.0 (17.8) 15.0
a [3.7, 26.3]
Follow-up 1
3 months after start therapy GAPS Motricity arm + leg 32 130.0 (44.0) 33 120.0 (42.0) 10.0 [-10.9,30.9]
26 weeks after start therapy Kwakkel Motricity leg 26 68.2 (25.3) 34 27.2 (26.8) 41.0 [27.7,54.3]
26 weeks after start therapy Kwakkel Motricity arm 29 48.6 (31.1) 34 31.1 (30.1) 17.5 [2.3,32.7]
3 months after stroke Rodgers Motricity arm 54 85.0 (20.0) 51 78.0 (36.3) 7.0 [-4.3,18.3]
Subtotal - Motricity arm 83 85 10.7 [1.7,19.8]
18 weeks after start therapy Cooke Knee extend
torque
19 56.4 (36.3) 18 37.9 (27.8) 18.5
a [-2.3, 39.3]
18 weeks after start therapy Cooke Knee flexion
torque
19 41.7 (28.8) 18 25.2 (22.9) 16.5
a [-0.2, 33.2]
3 months after start therapy Lincoln Hand grip strength 84 9.0 (28.2) 84 19.0 (43.0) -10.0 [-19.5,1.8]
Follow-up 2
6 months after start therapy Lincoln Hand grip strength 81 23.0 (40.7) 81 25.0 (45.2) -2.0 [-15.3,11.3]
6 months after stroke Rodgers Motricity arm 48 83.0 (28.2) 48 77.0 (25.9) 6.0 [-4.8,16.8]
6 months after start therapy GAPS Motricity arm + leg 30 124.0 (42.0) 34 121.0 (51.0) 3.0 [-19.8,25.8]
a= fixed effect model used;
b= random effect model used; FU = Follow-up; * = <0.05.
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Page 8 of 13No significant differences were found between the
two doses of therapy at follow-up 2 (three studies).
Meta-analysis was not possible.
2. Motor impairment - movement control (Table 7)
All of the outcome measures were made at 5 or 6 weeks
after the start of therapy but heterogeneity in measures
used between studies prevented meta-analysis. Effect
sizes were insignificant for all individual comparisons
and no trends were discernable in the data.
3. Functional activity (Table 8)
At outcome, data from one trial relating to River-
mead Mobility Index was omitted because only 3 of
35 participants in the extra therapy group appear to
have been included in the outcome data compared
to all participants in the control group [22]. There-
fore values provided may not have been representa-
tive of the entire group. Meta-analysis was
undertaken for Action Research Arm Test (3 stu-
dies) and comfortable walking speed (2 studies) with
effect sizes of 0.1 (-5.7,6.0] and 0.3 [0.1,0.5] respec-
tively. For other measures, the individual study com-
parisons found a trend towards a better outcome
with higher dose for most comparisons but this was
weaker than for motor impairment- muscle function.
Significance was only found in individual study com-
parisons in favour of extra therapy for: ability to
walk at 0.8 m/sec or more with an odds ratio of 3.9
[1.1,13.9] and maximal walking speed effect size, 0.4
[0.1,0.7]. A significant benefit for standard dose ther-
apy was found for one individual study comparison
for the Rivermead Gross Function score with effect
size -2.0 [-3.4,-0.6].
At follow-up-1 meta-analysis was undertaken for
Action Research Arm Test (2 studies), Rivermead
Mobility Score (2 studies) and comfortable walking
speed (2 studies) with non-significant effect sizes of
2.2 [-6.0,10.4], 1.0 [-0.6,2.5] and 0.2 [-0.1,0.4]
respectively. For other measures the significant effect
sizes from individual studies were: Rivermead Arm
score, -2.0 [-3.7,-0.3]; 5 metre walk time, -13.6
[-26.2,-1.0]; Functional Ambulation Categories, 1.0
[0.2,1.8]; and ability to walk at 0.8 m/sec or more,
2.8 [0.8,10.6].
The follow-up-2 meta-analysis (3 studies) found a
significant benefit for standard dose therapy for
ARAT, subtotal of -6.4 [-12.8,0.00]. A significant
benefit in favour of standard dose therapy was also
found from an individual study in respect of the
Rivermead Arm score with an effect size of -2.00
[-4.0,-0.1]. The benefit for higher dose therapy was,
however, maintained for Functional Ambulation
Category, 1.0 [0.4,1.6].
Discussion
This systematic review provides limited support for the
hypothesis that a higher dose of exercise-based therapy
enhances motor recovery after stroke. There are some
indications from the present meta-analysis for benefit
from a higher dose for: comfortable walking speed; max-
imum walking speed; and upper limb muscle function.
Meta-analysis was, however, limited by heterogeneity
between studies in the measures used and therefore
most estimates of effect size were derived from single
studies. Those single study sample estimates that were
statistically significant were mostly in favour of a higher
dose of therapy. In contrast, there are also some indica-
tions from meta-analysis for benefit from a standard
dose for hand grip force/strength and upper limb func-
tional ability at outcome (Table 6) and for ARAT score
at follow-up 2 (Table 8). Caution in interpretation of
the results of the present review is also raised by the
finding that only three of the seven included studies had
all design elements assessed as low risk of bias. Clearly
there are limitations to the current evidence base that
restrict the provision of clear guidance for whether an
increased dose of exercise-based therapy enhances
recovery after stroke.
Table 7 Motor impairment - movement control
Time-point Study Measure used Augmented therapy Standard therapy Mean difference
Number
subjects
Mean
(SD)
Number
subjects
Mean
(SD)
Effect
size
[95% CI]
Outcome
6 weeks after start therapy Cooke Symmetry step time 19 18.8 (35.6) 15 28.6 (33.1) 9.7
a [-32.9, 13.5]
6 weeks after start therapy Cooke Symmetry step length 19 13.5 (15.8) 15 25.0 (36.6) 11.5
a [-31.3, 8.3]
Follow-up 1
18 weeks after start therapy Cooke Symmetry step time 19 19.4 (29.9) 14 23.0 (23.5) 3.6
a [-21.9, 14.6]
18 weeks after start therapy Cooke Symmetry step length 19 23.7 (49.9) 14 12.3 (11.0) -11.4
a [-11.8, 34.6]
a= fixed effect model used;
b= random effect model used; FU = Follow-up; *==<0 . 0 5 .
Note: symmetry values represent difference from total symmetry therefore a higher value indicates a worse outcome.
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Page 9 of 13Table 8 Effect sizes for functional activity
Time-point Study Measure used Augmented therapy Standard therapy Mean difference
No.
subjects
Mean
(SD)
No.
subjects
Mean
(SD)
Effect
size
[95% CI]
Outcome
6 weeks after start therapy Donaldson ARAT 10 41.8 (17.8) 8 45.0 (14.0) 3.2 [-17.9,11.5]
20 weeks after start therapy Kwakkel ARAT 29 9.0 (28.9) 34 0.0 (1.5) 9.0 [-1.5,19.5]
5 weeks after start therapy Lincoln ARAT 87 1.0 (25.9) 90 5.0 (28.2) -4.0 [-12.0,4.0]
Subtotal - ARAT 126 132 0.1 [-5.7,6.0]
6 weeks after start therapy Donaldson 9 Hole Peg Test 10 0.2 (0.2) 8 0.2 (0.1) 0.0
a [-0.1,0.1]
5 weeks after start therapy Lincoln 10 Hole Peg Test 87 0.0 (19.3) 90 0.0 (41.5) 0.0
a [-9.5,9.5]
5 weeks after start therapy Lincoln Rivermead arm 87 3.0 (5.9) 90 4.0 (5.2) -1.0 [-2.6,0.6]
6 weeks after start therapy Cooke Rivermead mobility 31 36.6 (10.4) 32 34.6 (10.8) 2.0 [-3.2,7.2]
6 weeks after start therapy Cooke Walk 0.8 m/s or more 31 11 32 4 3.9
c [1.1,13.9]
6 weeks after start therapy Cooke Comfort walk speed 32 0.6 (0.5) 31 0.3 (0.4) 0.3 [0.1,0.5]
20 weeks after start therapy Kwakkel Comfort walk speed 26 0.7 (0.5) 34 0.4 (0.4) 0.3 [0.1,0.5]
Subtotal - comfort walk speed 58 65 0.3 [0.1,0.5]
20 weeks after start therapy Kwakkel Max walk speed 26 0.9 (0.7) 34 0.5 (0.6) 0.4 [0.1,0.7]
20 weeks after start therapy Kwakkel FAC 29 4 (1.5) 34 3 (2.2) 1.0 [0.1,2.0]
6 weeks after start therapy Partridge 5 metre walk time 33 49.2 (32.0) 22 39.9 (29.9) 9.3 [-7.3,25.9]
5 weeks after start therapy Lincoln Rivermead Gross
Function
87 3.0 (4.4) 87 5.0 (5.2) -2.0 [-3.4,-0.6]
Follow-up 1
26 weeks after start therapy Kwakkel ARAT 29 4.0 (28.2) 34 0.0 (1.85) 4.0 [-6.3,14.3]
3 months after stroke Rodgers ARAT 54 53.0 (27.4) 51 54.0 (41.5) -1.0 [-14.5,12.5]
Subtotal - ARAT 83 85 2.2 [-6.0, 10.4]
18 weeks after start therapy Cooke Rivermead mobility 28 36.6 (9.8) 23 39.7 (5.7) -3.1 [-7.4,1.2]
3 months after start therapy GAPS Rivermead mobility 32 9.7 (3.3) 34 8.1 (3.6) 1.6 [-0.1,3.3]
Subtotal - Rivermead mobility 60 57 1.0 [-0.6,2.5]
18 weeks after start therapy Cooke Comfort walk speed 27 0.6 (0.5) 23 0.4 (0.4) 0.2 [-0.1,0.5]
26 weeks after start therapy Kwakkel Comfort walk speed 26 0.6 (0.5) 34 0.4 (0.4) 0.2 [-0.0,0.4]
Subtotal - Comfort walk speed 59 61 0.2 [-0.1,0.4]
3 months after stroke Rodgers Frenchay Arm Test 54 4.0 (2.2) 51 4.0 (3.7) 0.0 [-1.2,1.2]
3 months after start therapy Lincoln Rivermead arm 84 3.0 (5.9) 84 5.0 (5.2) -2.0 [-3.7,-0.3]
6 months after start therapy Partridge 5 metre walk time 27 35.8 (16.5) 33 49.4 (32.1) -13.6 [-26.2,-1.0]
3 months after start therapy Lincoln Rivermead Gross
Function
84 5.0 (5.2) 84 6.0 (5.9) -1.0 [-2.7,0.7]
26 weeks after start therapy Kwakkel FAC 26 5.0 (0.7) 34 4.0 (2.2) 1.0 [0.2,1.8]
18 weeks after start therapy Cooke Walk 0.8 m/s or more 27 10 23 4 2.8 [0.8,10.6]
26 weeks after start therapy Kwakkel Max walk speed 26 0.9 (0.7) 34 0.6 (0.6) 0.3 [-0.0,0.6]
Follow-up 2
6 months after start therapy Lincoln ARAT 81 3.0 (28.9) 81 19.0 (33.3) -16.0 [-25.6,-6.4]
52 weeks after start therapy Kwakkel ARAT 28 6.0 (31.3) 33 1.0 (21.1) 5.00 [-8.6,18.7]
6 months after stroke Rodgers ARAT 48 55.0 (31.9) 48 56.0 (23.7) -1.0 [-12.2,10.2]
Subtotal - ARAT 157 162 -6.4 [-12.8,0.0]
6 months after start therapy Lincoln 10 Hole Peg Test 81 0 (40.7) 81 0 (45.2) 0.0 [-13.3,13.3]
6 months after stroke Rodgers Frenchay Arm Test 48 5.0 (3.0) 48 4 (3.0) 1.0 [-0.2,2.2]
6 months after start therapy Lincoln Rivermead arm 81 4.0 (6.7) 81 6.0 (5.9) -2.0 [-4.0,-0.1]
6 months after start therapy Lincoln Rivermead Gross
Function
81 6.0 (5.9) 81 7.0 (3.7) -1.0 [-2.5,0.5]
52 weeks after start therapy Kwakkel Max walk speed 25 0.9 (0.6) 33 0.7 (0.6) 0.2 [-0.1,0.5]
52 weeks after start therapy Kwakkel FAC 25 5 (0.7) 33 4 (1.48) 1.0 [0.4,1.6]
6 months after start therapy GAPS Rivermead mobility 30 10.2 (3.1) 34 9.1 (4.0) 1.1 [-0.6,2.8]
52 weeks after start therapy Kwakkel Comfort walk speed 25 0.6 (0.5) 33 0.5 (0.4) 0.1 [-0.1,0.3]
a= fixed effect model used;
b= random effect model used;
c= odds ratio used; FU = Follow-up; *= = <0.05; ARAT = Action Research Arm Test; FAC = Functional
Ambulation Category.
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extra therapy of: earlier systematic reviews [1-5] and
experimental human studies (for example [12]). But,
maybe this result is not so surprising considering that
animal model studies and a clinical trial found that
higher doses of therapy produced worse outcomes early
after stroke [6-10]. Interestingly the detrimental effect
found in the present systematic review on hand grip
force/strength (Table 6) and upper limb function as
measured by the ARAT (Table 8) emanate from trials
conducted early after stroke [21,24]. It is possible there-
fore that there is a negative interactional effect between
time from stroke and dose. However, other trials
included in the present review were also conducted with
participants early after stroke and detrimental effects
w e r en o tf o u n df o re i t h e ru p p e rl i m bo rl o w e rl i m b
motor impairment or activity. Prospective robust clinical
trials are needed to investigate whether time after stroke
influences motor response to different doses of exercise-
based therapies.
A starting dose for subsequent trials is suggested by
an earlier systematic review which concluded that a 16-
hour difference in treatment time between experimental
and control groups provided in the first 6 months after
stroke is needed to obtain significant differences in
activities of daily living” [3]. Investigation of the data
reported here for a potential dose-response relationship
is limited by the relatively small number of comparisons
that can be included in a meta-analysis because of the
variation in measures used in included studies. We were
concerned to avoid undertaking analyses of sets of het-
erogeneous measures in a single meta-analysis. However,
visual inspection of outcome time-point data (Tables 6,7
and 8) and data on dose (Table 4) suggests a trend for
better outcome with higher dose. The highest doses,
however, were of task-specific interventions [18-20]
whereas the smaller doses consisted of UK conventional
physical therapy [25,26]. This difference could have
influenced the results of the present review. It is also
possible that differences in effect sizes between studies
could be due to differences in underlying standard care.
The study by Kwakkel and colleagues [18-20] was con-
ducted in the Netherlands whereas the other four stu-
dies took place in the United Kingdom. This could have
influenced the results of the present review because
there may be important differences in underlying rou-
tine care between centres and countries [27]. There may
also be differences in standard therapy over time [28].
Therefore the differences in clinical setting for studies
may also be influential on outcome. Consequently, this
present review which restricted included studies to
those investigating different doses of the same therapy
to avoid the confound of different types of therapy may
itself be confounded by the inclusion of different types
as well as different intensities of therapy. Essentially this
systematic review highlights the need for prospective
dose-ranging studies of specific interventions before
undertaking efficacy studies.
None of the doses investigated in included studies
emerged from preliminary dose-finding studies. The
same observation emerged from in a systematic review
and meta-analysis of electrostimulation [29]. Indeed
dose-finding has not featured prominently as a precur-
sor to stroke rehabilitation trials [30,31] Without pre-
cursor dose-finding studies it is possible that the studies
included in this review investigated sub-optimal doses of
exercise-based therapies. The case for prospective dose-
finding studies as precursors to Phase II and phase III
trials of rehabilitation has been made already [30,31].
Nevertheless, we are aware of only one study designed
to investigate the relative efficacy of three or more doses
of the same rehabilitation therapy [Hunter SM, Ham-
mett L, Ball S, Smith N, Anderson C, Clark A, Tallis R,
Rudd A, Pomeroy VM. Appropriate dose of Mobilisation
and Tactile Stimulation to enhance upper limb recovery
early after stroke: a randomised controlled trial. Sub-
mitted]. Dose-finding has not featured prominently as a
precursor to phase II and phase III trials of rehabilita-
tion therapies.
A potential limitation to the present review is the
examination of multiple data sets from the same study
participants. Therefore bias is potentially present
through the repeated use of results arising from the
same group of participants. In recognition of this possi-
bility the present review did not combine data from the
same studies within meta-analyses.
Another potential limitation is that the present review
may be influenced by a publication bias as the literature
search excluded studies written in a language other than
English. A strong publication bias is, however, unlikely
to be present the studies included in this present review
were also included in previous meta-analyses. In addi-
tion, authors of included studies were contacted for any
unpublished data.
Conclusions
The findings indicate that there is limited empirical
evidence to inform clinical decisions on how much
exercise-based therapy is needed to enhance motor
recovery after stroke. To the best of our knowledge the
present systematic review of the effects of dose of ther-
apy is the first to control for the potential confounder
of different types of intervention. It has refined and
updated knowledge of the effects on motor recovery of
the provision of an increased dose of exercise-based
therapy after stroke. It has highlighted the clinical
uncertainty around dose. Further systematic reviews
are unlikely to resolve this clinical uncertainty because
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Page 11 of 13of the heterogeneity between exercise-based therapies
in included studies and the apparent lack of dose-find-
ing studies undertaken as precursors to robust clinical
trials. The results of the present systematic review
therefore indicate a need to undertake dose-finding
studies of specific exercise-based interventions as pre-
cursors to robust clinical trials.
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